SRR12696741
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.700
- MYC_TARGETS_V1+0.600
- MYC_TARGETS_V2+0.600
- OXIDATIVE_PHOSPHORYLATION+0.600
- G2M_CHECKPOINT+0.500
- MTORC1_SIGNALING+0.500
- UNFOLDED_PROTEIN_RESPONSE+0.500
- DNA_REPAIR+0.400
- INTERFERON_ALPHA_RESPONSE+0.400
- INTERFERON_GAMMA_RESPONSE+0.400
Top 10 suppressed
- APICAL_JUNCTION-0.300
- HEDGEHOG_SIGNALING-0.300
- APICAL_SURFACE-0.200
- COAGULATION-0.200
- KRAS_SIGNALING_DN-0.200
- KRAS_SIGNALING_UP-0.200
- MYOGENESIS-0.200
- TGF_BETA_SIGNALING-0.200
- ESTROGEN_RESPONSE_EARLY-0.100
- UV_RESPONSE_DN-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | A07BA2E1-CCA0-4231-A391-B13383A2BCB9 | — | — | 0.895 |
| 2 | E97A62A3-E4D3-435C-9165-C0075358578E | — | — | 0.870 |
| 3 | SJEPD030391_D1.RNA-Seq | EPN | Supratentorial EPN | 0.867 |
| 4 | TCGA-38-4625-01A-01R-1206-07 | — | cohortA1 | 0.864 |
| 5 | SRR35579824 | — | E | 0.857 |
| 6 | AA605CB6-ABD9-4802-8784-75A18A74C87B | — | — | 0.856 |
| 7 | 5F350242-0CF6-43AC-AB06-2C130D85C5CC | — | — | 0.851 |
| 8 | MDT-AP-0368 | Med | Medulloblastoma | 0.851 |
| 9 | E7BE221B-273D-4C04-BE79-366E6455EFBC | — | — | 0.850 |
| 10 | 17-020P2_Bladder | — | — | 0.850 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.700 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.600 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.600 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.600 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.500 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.500 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.500 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.400 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.400 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.400 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.300 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.300 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.300 | Inavolisib | — uncovered |
| HYPOXIA | 0.300 | Idelalisib | — uncovered |
| PEROXISOME | 0.300 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.300 | Idelalisib | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |